A selective, competitive inhibitor of HMG-CoA reductase, it lowers plasma cholesterol and lipoprotein levels, increases the number of LDL receptors on the surface of liver cells to enhance the uptake and catabolism of low-density lipoproteins, lowers total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) plasma levels, regulates high-density lipoprotein cholesterol levels, and improves a variety of dyslipidemia conditions.

This product is a statin blood lipid regulating drug, belonging to the HMG-CoA reductase inhibitor. It is inactive itself. The hydrolysis product after oral absorption competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.

It does not affect the metabolism of antipyrine. When used in combination with colestipol, it can enhance the LDL-C lowering effect. There is no significant change when used in combination with cimetidine. The steady-state blood concentration of digoxin increases by 20%. When used in combination with erythromycins, the plasma concentration increases by 40%. When used in combination with oral contraceptives, the areas under the curve of norethindrone and ethinyl estradiol increase by 30% and 20%, respectively. It has no effect on the clotting time of warfarin. No clinical adverse interactions were found with antihypertensive drugs and estrogen replacement therapy.

Amlodipine is a dihydropyridine calcium antagonist that can inhibit calcium ions from crossing the membrane into vascular smooth muscle and myocardium, reduce peripheral vascular resistance and blood pressure, and relieve angina pectoris.

Dihydropyridine calcium antagonists selectively inhibit calcium ions from entering smooth muscle cells and myocardial cells across the membrane, thereby reducing peripheral vascular resistance and lowering blood pressure. They can also reduce myocardial oxygen demand and relieve angina pectoris. They do not affect plasma calcium concentration, and long-term use does not cause significant changes in heart rate or plasma catecholamines.